Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy

An appropriate bifunctional chelating agent namely DOTA-Ph-Al was developed for the conjugation with biological vectors (anti EGFr antibody). We hereby report the synthesis of p-bromoacetamidobenzyl derivative of DOTA and its conjugation to monoclonal antibody anti-EGFR ior egf/r3. Immunoconjugate was prepared by conjugation of p- bromoacetamidobenzyl derivative of DOTA with ior egf/r3. Modified antibody was purified on size exclusion chromatography. DOTA-Ph-Al-ior egf/r3 exhibited quantitative 99mTc labeling (>96%) with specific activity 10-20 mCi/mg of protein and 90Y- labeling with specific activity 2-5 mCi/mg. Immunoreactivity was determined by flow cytometry. Receptor ligand assay on murine cell line EAT and human tumor cell line U- 87MG showed Kd =2.87 nM and 4.86 nM respectively. The stability in serum indicated that 99mTc remained bound to antibodies up to 24h and 98% 90Y was associated with the mAb for 5 days. Biodistribution characteristics of Ab-conjugate radiolabeled to 99mTc and 90Y radionuclide was examined in BALB/c mice grafted with EAT and athymic mice with U-87MG cell line demonstrated high tumor uptake with 5.5 ± 1.3 and 7.85 ± 1.2 %ID/g at 4 and 24 h for 99mTc- DOTA-Ph-Al-ior egf/r3 in EAT tumors after post injection respectively. Maximal radiotracer uptake peaked 17.6 ± 2.5 %ID/g in EAT tumor and 12.89 ± 0.66 % ID/g in U-87MG tumor at 48h for 90Y. The drug excreted through renal routes as the activity in the kidneys was 13.42 ± 0.33 %ID/g at 1h and 4.51± 1.2 %ID/g at 4h for 99mTc- DOTA-Ph-Al-ior egf/r3.

[1]  Damon L. Meyer,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.

[2]  A. Sherry,et al.  Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N,N',N"-triacetic acid and 1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid , 1987 .

[3]  Shuang Liu,et al.  Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. , 2001, Bioconjugate chemistry.

[4]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[5]  J. P. Cox,et al.  Structure and Solution Stability of Indium and Gallium Complexes of 1, 4,7‐Triazacyclononanetriacetate and of Yttrium Complexes of 1,4,7,10‐ Tetraazacyclododecanetetraacetate and Related Ligands: Kinetically Stable Complexes for Use i , 1991 .

[6]  T. Waldmann,et al.  Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. , 1989, Cancer research.

[7]  C. Beglinger,et al.  Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy. , 2000, Endocrinology.

[8]  K. Lamborn,et al.  Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Denardo,et al.  Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. , 1995, Cancer research.

[10]  G. Denardo,et al.  Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Arthur E. Martell,et al.  Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles , 1991 .

[12]  C. Meares.  Chelating agents for the binding of metal ions to antibodies. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[13]  Shuang Liu,et al.  Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for (90)Y- and (111)In-labeled DOTA-biomolecule conjugates. , 2002, Bioconjugate chemistry.

[14]  H. Modjtahedi,et al.  The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). , 1994, International journal of oncology.

[15]  Min Li,et al.  Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. , 1993, Bioconjugate chemistry.

[16]  B. Wessels,et al.  Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. , 1984, Medical physics.

[17]  S. Denardo,et al.  Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method. , 1994, Bioconjugate chemistry.

[18]  A. Mishra,et al.  A New Bifunctional Chelating Agent Conjugated with Monoclonal Antibody and Labelled with Technetium-99m for Targeted Scintigraphy: 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecane , 2004, Journal of drug targeting.

[19]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[20]  M. Melamed,et al.  Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. , 1986, Cancer research.

[21]  W. Goddard,et al.  Mechanism and Energetics for Complexation of 90Y with 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA), a Model for Cancer Radioimmunotherapy , 1999 .

[22]  R. Sharma,et al.  Synthesis of novel bifunctional Schiff-base ligands derived from condensation of 1-(p-nitrobenzyl)ethylenediamine and 2-(p-nitrobenzyl)-3-monooxo-1,4,7-triazaheptane with salicylaldehyde , 2003 .

[23]  A. Martell,et al.  Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands , 1991 .

[24]  G. Denardo,et al.  Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  A. Lage,et al.  Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  J. Shively,et al.  A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. , 1994, Bioconjugate chemistry.

[27]  D. Keire,et al.  NMR studies of the metal-loading kinetics and acid-base chemistry of DOTA and butylamide-DOTA. , 1999, Bioconjugate chemistry.

[28]  D. Scheinberg,et al.  A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. , 1995, Nuclear medicine and biology.

[29]  A. Rajasekaran,et al.  Biological impediments to monoclonal antibody-based cancer immunotherapy. , 2004, Molecular cancer therapeutics.

[30]  M. Teitell,et al.  The evolution of antibodies into versatile tumor-targeting agents. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[32]  C. Meares,et al.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. , 1984, Analytical biochemistry.

[33]  P. Stoppioni,et al.  Theoretical investigation on the geometries of DOTA and DOTA-like complexes and on the transition states of their conformational equilibria , 2002 .

[34]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.